Cartography Biosciences and Samsung Ventures announced a strategic investment designed to support the advancement of Cartography’s oncology pipeline and the expansion of its proprietary drug discovery platform.
The investment was made through the Samsung Life Science Fund, which was established by Samsung Biologics, Samsung Bioepis, and Samsung C&T and is managed by Samsung Ventures. The fund focuses on biopharmaceutical companies developing next-generation technologies across biologics, gene editing, and AI-enabled therapeutics.
Cartography Biosciences said the partnership is intended to accelerate development of novel cancer therapies by combining the company’s antigen discovery and drug development capabilities with Samsung’s life sciences investment and strategic development expertise.
The company develops antibody-based oncology therapies using its ATLAS and SUMMIT discovery platforms, which integrate proprietary single-cell datasets, computational biology, and target validation technologies to identify tumor-restricted antigens and antigen combinations. Cartography said the platform is designed to improve therapeutic specificity and therapeutic index for antibody-based cancer treatments.
Cartography is currently advancing a pipeline of oncology programs targeting unmet medical needs. Its lead candidate, CBI-1214, is a T-cell engager therapy for colorectal cancer that entered Phase 1 clinical development earlier this year and is currently enrolling patients.
The company said its discovery platforms are powered by large-scale proprietary datasets spanning healthy tissue cell states and patient tumor profiling, combined with machine learning and AI-driven biological analysis.
Samsung Ventures said the investment reflects its interest in supporting innovative biopharmaceutical technologies capable of transforming cancer treatment approaches.
KEY QUOTES:
“Samsung Ventures is an ideal partner as we continue to advance our mission of precisely mapping tumor biology to develop highly differentiated antibody-based therapies. We are excited to partner with a global leader that recognizes the value of new technologies and cutting-edge biologic engineering in the discovery of novel biopharmaceuticals.”
Kevin Parker, Chief Executive Officer, Cartography Biosciences
“Cartography Biosciences represents a new generation of biotechnology innovation, combining large-scale data, computational biology, and therapeutic design to unlock novel cancer therapies. This investment reflects our commitment to supporting innovative technologies with the potential to transform treatment paradigms and deliver meaningful impact to patients worldwide.”
Dr. Joseph Jeong, Executive Vice President And Head Of Bio R&D Center, Samsung Biologics
